STAT3 Relays a Differential Response to Melanoma-Associated NRAS Mutations

Related Experiment Video

Updated: Dec 31, 2025

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

9.3K

James Kim1,2, Daniel Novak1,2, Christos Sachpekidis3

  • 1Skin Cancer Unit, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Cancers
|January 8, 2020
PubMed

Insights

NRAS-mutant melanoma patients lack targeted therapies. This study identifies the AXL/STAT3 pathway as crucial in NRASQ61 mutations, suggesting new therapeutic strategies for this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • NRAS mutations occur in 20% of melanomas, leading to poorer outcomes compared to wild-type or BRAF-mutated cases.
  • Currently, no targeted therapies exist for NRAS-mutated melanoma, unlike BRAF-mutated melanoma treated with BRAF/MEK inhibitors.
  • Identifying NRAS downstream targets is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the impact of different NRAS mutations (codon 12, 13, 61) on melanoma cell behavior.
  • To identify key molecular pathways regulated by NRAS mutations in melanoma.
  • To explore potential therapeutic targets for NRAS-mutated melanoma.

Main Methods:

  • Studied oncogene-induced senescence, cell proliferation, migration, and colony formation in melanocytes and melanoma cell lines with various NRAS mutations.
  • Utilized immortalized melanocytes and melanoma cell lines.
  • Analyzed the role of the AXL/STAT3 axis in NRASQ61-induced oncogene-induced senescence.

Main Results:

  • Identified the AXL/STAT3 axis as a key regulator of NRASQ61-induced oncogene-induced senescence (OIS).
  • Demonstrated that NRASQ61 mutations are more tumorigenic than NRASG12/13 mutations.
  • Observed a correlation between NRASQ61 mutations and STAT3 activation.

Conclusions:

  • NRASQ61 mutations exhibit increased tumorigenicity and are linked to STAT3 activation.
  • The AXL/STAT3 pathway plays a significant role in NRASQ61-driven melanoma.
  • These findings provide evidence for STAT3's tumorigenic role in NRAS-mutant melanomas and may inform future therapy strategies.
Keywords:
NRASSTAT3melanomamutationoncogene-induced senescence

More Related Videos

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression11:02

The Three-Dimensional Human Skin Reconstruct Model: a Tool to Study Normal Skin and Melanoma Progression

Published on: August 3, 2011

50.7K
A 3D Organotypic Melanoma Spheroid Skin Model08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

16.4K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
7.0K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
7.7K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
4.5K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
5.2K